Clinical application of new crown vaccine in China


“I just feel that I just meet the requirements, I don’t have too much burden, I can bear the results, and occasionally I want to break away from the ordinary people. What I really want to thank is all the people standing in front of the ordinary people.” Xiaomi (pseudonym), a volunteer in the first phase clinical trial of the new crown vaccine, has always felt that he is an ordinary person. She didn’t know how to reply to the attention that came.
Before that, the girl posted a buyer show on Weibo, praising the shopkeeper’s pants. By the way, she wore those pants as a volunteer and was vaccinated with the new crown vaccine.
All of a sudden, the girl’s comment area was full of compliments and blessings.
Some say that they are people and human pathfinders.
Previously, Wang Junzhi, academician of the Chinese Academy of engineering, said at a press conference that there are units that have made relatively rapid progress in research and development in China. They have submitted clinical trial application materials to the State Food and Drug Administration in a rolling manner, and have carried out clinical trial scheme demonstration, recruitment of volunteers and other related work.
Xiaomi was one of the first volunteers. A novel coronavirus (2019-COV) vaccine (adenovirus vector) phase I clinical trial was introduced.
According to the public information on the China clinical trial registration center, the sponsor of the trial is the Institute of bioengineering of the Medical Research Institute of the Academy of Military Sciences and kangxinuo biology Co., Ltd.
The purpose of the experiment is to test and evaluate the safety and effectiveness of recombinant new coronavirus vaccine (adenovirus vector).
A novel coronavirus S antigen was expressed by the recombinant human adenovirus type 5, which was constructed by genetic engineering.
Chen Wei, the project leader, academician of the Chinese Academy of engineering and researcher of the Academy of military medicine, explained its principle as follows: under the premise of “learning” the virus, carry out “surgery” on the virus, use the method of transplanting flowers and trees to reconstruct a vector virus we need, and inject it into the human body to generate immunity.
There are not many volunteers needed for phase I test, only permanent residents in Wuhan area, residents with registered permanent residence in Wuchang, Hongshan and Donghu scenic spots are preferred, aged 18-60.
The volunteers will be divided into three groups: low dose group, medium dose group and high dose group, 36 people in each group.
After screening and physical examination, qualified volunteers can be vaccinated. The next 14 days were the period of concentrated isolation and observation.